Zymenex A/S - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 30 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Zymenex A/S - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Zymenex A/S - Product Pipeline Review - 2014', provides an overview of the Zymenex A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Zymenex A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Zymenex A/S including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Zymenex A/S's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Zymenex A/S's pipeline products

Reasons to buy

- Evaluate Zymenex A/S's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Zymenex A/S in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Zymenex A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Zymenex A/S and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Zymenex A/S
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Zymenex A/S and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Zymenex A/S Snapshot 5
Zymenex A/S Overview 5
Key Information 5
Key Facts 5
Zymenex A/S - Research and Development Overview 6
Key Therapeutic Areas 6
Zymenex A/S - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Zymenex A/S - Pipeline Products Glance 10
Zymenex A/S - Late Stage Pipeline Products 10
Phase III Products/Combination Treatment Modalities 10
Zymenex A/S - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Zymenex A/S - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Zymenex A/S - Drug Profiles 14
Recombinant Human Alpha-Mannosidase 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
ACE-527 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
ACE-920 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Galaczym 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ZA-011 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Zymenex A/S - Pipeline Analysis 21
Zymenex A/S - Pipeline Products by Target 21
Zymenex A/S - Pipeline Products by Route of Administration 22
Zymenex A/S - Pipeline Products by Molecule Type 23
Zymenex A/S - Pipeline Products by Mechanism of Action 24
Zymenex A/S - Recent Pipeline Updates 25
Zymenex A/S - Dormant Projects 26
Zymenex A/S - Discontinued Pipeline Products 27
Discontinued Pipeline Product Profiles 27
Porphozym 27
Zymenex A/S - Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30

List of Tables
Zymenex A/S, Key Information 5
Zymenex A/S, Key Facts 5
Zymenex A/S - Pipeline by Indication, 2014 7
Zymenex A/S - Pipeline by Stage of Development, 2014 8
Zymenex A/S - Monotherapy Products in Pipeline, 2014 9
Zymenex A/S - Phase III, 2014 10
Zymenex A/S - Phase II, 2014 11
Zymenex A/S - Preclinical, 2014 12
Zymenex A/S - Discovery, 2014 13
Zymenex A/S - Pipeline by Target, 2014 21
Zymenex A/S - Pipeline by Route of Administration, 2014 22
Zymenex A/S - Pipeline by Molecule Type, 2014 23
Zymenex A/S - Pipeline Products by Mechanism of Action, 2014 24
Zymenex A/S - Recent Pipeline Updates, 2014 25
Zymenex A/S - Dormant Developmental Projects,2014 26
Zymenex A/S - Discontinued Pipeline Products, 2014 27
Zymenex A/S, Other Locations 28